# BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination

> **NCT03991442** · PHASE3 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 257 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Fimasartan/Amlodipine

## Key facts

- **NCT ID:** NCT03991442
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-17
- **Primary completion:** 2021-03-02
- **Final completion:** 2021-03-02
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03991442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03991442, "BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03991442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*